GRML vs IKT

Greenland Mines Ltd vs Inhibikase Therapeutics, Inc. — Valuation Comparison 2026

GRML

Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd
Quality
4.6
out of 10
Value Trap
22
SAFE
Price
$0.36
Last close
Models
7/13
Active
VS

IKT

Biological Products, (No Diagnostic Substances)
Inhibikase Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$1.75
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType GRML Fair ValueGRML Upside IKT Fair ValueIKT Upside
Bayesian DCF Intrinsic $0.12 -66.6% $0.66 -62.4%
Earnings Power Value Intrinsic $0.34 -82.4%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.17 -51.0% $1.03 -41.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRML vs IKT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRML vs IKT — Which Stock Is More Undervalued?

GRML scores higher with a 4.6/10 quality rating vs IKT's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Greenland Mines Ltd (GRML) and Inhibikase Therapeutics, Inc. (IKT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRML currently trades at $0.36 with a QOC of 4.6/10, while IKT trades at $1.75 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).